等待開盤 09-18 09:30:00 美东时间
-0.280
-5.19%
Athira Pharma announced a 10-for-1 reverse stock split to increase its share price, aiming to meet Nasdaq's $1.00 minimum bid price requirement and improve liquidity and investor interest. The split will take effect on September 17, 2025, with shares trading under the new adjusted price from September 18. Each 10 shares will combine into 1, reducing the total authorized shares from 900 million to 90 million. Fractional shares will be paid in cash...
09-11 13:00
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) — Aether Holdings, Inc. (Nasdaq: ATHR) announced the expansion of its Alpha Edge Media™ division with the launch of six new branded newsletters covering equities, IPOs, small-caps, digital assets, and investor communities, along with its flagship Alpha Edge Summit™. These publications aim to grow a free and eventually paid subscriber base while providing critical data to support Aether Labs' AI models. The...
08-27 12:30
Alpha Edge Media, Inc. will host the Alpha Edge Summit Hong Kong 2025 on August 27, 2025, at Cloud 39, The Henderson building in Hong Kong. This exclusive event, themed "Where Alpha Meets Access: Institutional Strategies for a Digital Financial Future," will bring together over 200 influential digital asset investors, venture capitalists, blockchain innovators, and media voices during Bitcoin Asia Week. The summit features keynote addresses, pane...
08-20 12:30
Aether Holdings (NASDAQ:ATHR) reported quarterly losses of $(0.08) per share. This is a 166.67 percent decrease over losses of $(0.03) per share from the same period last year. The company reported $342.411 thousand in
08-20 05:44
Athira Pharma presented Phase 1 trial results for ATH-1105, a novel small molecule targeting neurodegenerative diseases like ALS, at the ALS Nexus 2025 conference. The trial, involving 80 healthy volunteers, demonstrated favorable safety, tolerability, and CNS penetration, supporting further development of the drug candidate. ATH-1105 aims to modulate the neurotrophic HGF system to restore neuronal health. The company highlighted the potential of...
08-14 11:00
<p style="font-family: Arial, sans-serif;"> Athira Pharma reported positive Phase 1 clinical trial results for ATH-1105, showing favorable safety, tolerability, and CNS penetration, supporting its development for ALS. The company paused fosgonimeton's development and is exploring strategic alternatives. Financials showed reduced cash, lower R&D and G&A expenses, and a narrowed net loss. </p>
08-07 20:05
计划长期储备比特币,MFH飙涨超50%;公司获高额溢价收购,CIO大涨超24%;与甲骨文达成供电合作,BE大涨23%>>
07-25 19:50
Aether Holdings (NASDAQ:ATHR) has commenced an underwritten public offering of units with expected gross proceeds of about $40 million. Aether expects to use approximately 85% of the net proceeds from...
07-21 20:33
<p>Aether Holdings, Inc. (NASDAQ: ATHR), a financial technology holding company, has announced an underwritten public offering of units expected to raise approximately $40 million in gross proceeds. The company plans to use 85% of the net proceeds to acquire bitcoin as part of a new bitcoin treasury strategy and 15% for working capital. Each Unit includes one share of common stock and one publicly traded warrant. The offering is expected to price...
07-21 12:26
Aether Holdings (NASDAQ:ATHR) was surging after its unit Alpha Edge Media announced on Thursday an entry into digital asset content vertical with the acquisition of AltcoinInvesting.co. Shares were +5...
07-17 20:41